Unusual structure-genotoxicity relationship in mouse lymphoma cells observed with a series of kinase inhibitors

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 746, Issue 1, 2012, Pages 21-28

  Fellows, Michael D ^a   Luker, Tim ^a   Cooper, Anne ^a   O'Donovan, Michael R ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Genotoxicity; In vitro micronucleus assay; Kinase inhibitors; Mouse lymphoma assay

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); PHOSPHOTRANSFERASE INHIBITOR; QUINOLONE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL STRUCTURE; GENOTOXICITY; IN VITRO STUDY; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; LYMPHOMA; MICE; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; MUTAGENS; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

MAMMALIA;

EID: 84860373682     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2012.03.006     Document Type: Article

References (12)

1. Smart D.J. Genotoxicity of topoisomerase II inhibitors: an anti-infective perspective. Toxicology 2008, 254:192-198.
2. +/- 3.7.2C mouse lymphoma cell line. Environ. Mol. Mutagen. 2006, 47:127-131.
3. Mortelmans K., Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat. Res. 2000, 455:29-60.
4. Mortelmans K., Riccio E.S. The bacterial tryptophan reverse mutation assay with Eschericia coli WP2. Mutat. Res. 2000, 455:61-69.
5. Clements J. The mouse lymphoma assay. Mutat. Res. 2000, 455:97-110.
6. Moore M.M., Honma M., Clements J., Bolcsfoldi G., Burlinson B., Cifone M., Clarke J., Delongchamp R., Durward R., Fellows M., Gollapudi B., Hou S., Jenkinson P., Lloyd M., Majeska J., Myhr B., O'Donovan M., Omori T., Riach C., San R., Stankowski L.F., Thakur A.K., Van Goethem F., Wakuri S., Yoshimura I. Mouse lymphoma thymidine kinase gene mutation assay: follow-up meeting of the International Workshop on Genotoxicity Testing - Aberdeen, Scotland, 2003 - assay acceptance criteria, positive controls, and data evaluation. Environ. Mol. Mutagen. 2006, 47:1-5.
7. Itoh T., Mitsumori K., Kawaguchi S., Sasaki Y.F. Genotoxic potential of quinolone antimicrobials in the in vitro comet assay and micronucleus test. Mutat. Res. 2006, 603:135-144.
8. Takahashi N., Shiragiku T., Itoh T., Kaneko E., Shibahara T., Kanbe T., Yamashita S. In vitro clastogenicity of optical isomers of nadifloxacin. Arzneimittelforschung 1994, 44:1265-1268.
9. Vock E.H., Lutz W.K., Hormes P., Hoffmann H.D., Vamvakas S. Discrimination between genotoxicity and cytotoxicity in the induction of DNA double-strand breaks in cells treated with etoposide, melphalan, cisplatin, potassium cyanide, Triton X-100, and gamma-irradiation. Mutat. Res. 1998, 413:83-94.
10. Ma G.Z., Zheng K.W., Jiang Y.J., Zhao W.N., Zhuang S.L., YU Q.S. Minor groove binding between norfloxacin and DNA duplexes in solution: a molecular dynamics study. Chin. Chem. Lett. 2005, 16:1367-1370.
11. Chiarugi A., Meli E., Calvani M., Picca R., Baronti R., Camaioni E., Costantino G., Marinozzi M., Pellegrini-Giampietro D.E., Pellicciari R., Moroni F. Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J. Pharmacol. Exp. Ther. 2003, 305:943-949.
12. Marzin D. Notion of threshold in mutagenesis: implications for mutagenic and carcinogenic risk assessment. Ann. Pharm. Fr. 2007, 65:404-414.